Brian S. Barnett, MD

Cleveland Clinic Psychiatric Treatment Resistance Program, Cleveland Clinic, Cleveland, Ohio

  • 4Articles
  • 9.2KReads1
  • 2023–2026Active
  • 26Collaborators
  • 3Citations2

About

Brian S. Barnett, MD, is affiliated with the Cleveland Clinic Psychiatric Treatment Resistance Program in Cleveland, Ohio. His publications focus on psychiatry topics including psychedelics, depression, electroconvulsive therapy, and sleep. His work addresses psychological and medical complications of psychedelic use, cognitive effects of ketamine and electroconvulsive therapy in treatment-resistant depression, and prescribing patterns of Z-drugs in primary care. Barnett has collaborated frequently with Erin Mauney, Fernando Espi Forcen, Franklin King IV, Juliana Zambrano, and Kabir Nigam.

Publications

PCC
Psychological Adverse Effects of Psychedelic Use
Rounds in the General Hospital

Psychological Adverse Effects of Psychedelic Use

June 25, 2026

This case-based review explores psychological adverse effects of psychedelic use, covering risk factors, trauma history, phenomenology, and evidence-based management strategies for clinicians.
, , , et al
PCC
Medical Complications of Psychedelics
Rounds in the General Hospital

Medical Complications of Psychedelics

June 23, 2026

This case-based review covers acute complications, drug interactions, and long-term safety across psilocybin, MDMA, ketamine, and ibogaine, with practical guidance for clinicians.
, , , et al
JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Coprescribing of Z-Drugs and Opioids During COVID-19
Original Research

Coprescribing of Z-Drugs and Opioids During COVID-19

September 11, 2023

Coprescribing of nonbenzodiazepine sedative-hypnotics, or “Z-drugs,” with opioids was more common among older patients, although the odds of coprescription among patients overall decreased over the COVID-19 lockdown period.
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe